Artwork

Content provided by DSI, Meranda Parascandola, and Ed Narke. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DSI, Meranda Parascandola, and Ed Narke or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

014 - Why now is the most important time for selecting a CMO

48:01
 
Share
 

Manage episode 277251871 series 2821798
Content provided by DSI, Meranda Parascandola, and Ed Narke. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DSI, Meranda Parascandola, and Ed Narke or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

What We Covered

  • 01:19 – Ed, Brian and Meranda welcome to the show Dr. Rick Offerman who speaks to his experience as a process chemist, the drug development process and what goes into selecting a solvent
  • 15:41 – The importance of selecting the right CMO partner
  • 19:05 – Questions that must be asked in the beginning of the drug manufacturing process
  • 23:14 – Dr. Rick breaks down best practices in cost-control
  • 30:16 – The importance of the project timeline
  • 40:13 – Dr. Rick takes a moment to recognize those who greatly influenced his career
  • 46:23 – Ed, Brian and Meranda thank Dr. Rick for joining the show

Tweetable Quotes

“A lot of CMOs are now going to a ‘one-stop shop’ type model. So basically they’ll say, ‘Yeah we’ll take you all the way from gram quantities right through commercial. We can do your API and your drug substance.’ But there’s still a lot of smaller shops out there that can do small scale pre-clinical work.”

“Cost is always a factor [in selecting a solvent] but it’s not the major one.”

“You’re gotta have an integrated approach all the way through the system to understand the API that you’re producing, the impurity profile, the crystal morphology, the polymorphs, that sort of thing.”

“Realistically, when you look at the cost of an API as a percentage of a drug product, it’s usually fairly low.”

“If the analytical people aren’t up and ready to go, then when the chemists start running stuff in the hoods, how do they analyze it? We don’t have methods, so we’re kinda going on a wing and a prayer.”

Relevant Links

Design Space InPharmatics - LinkedIn

Design Space InPharmatics - Twitter

Edward Narke on LinkedIn

Rick Offerman on LinkedIn

  continue reading

27 episodes

Artwork
iconShare
 
Manage episode 277251871 series 2821798
Content provided by DSI, Meranda Parascandola, and Ed Narke. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DSI, Meranda Parascandola, and Ed Narke or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

What We Covered

  • 01:19 – Ed, Brian and Meranda welcome to the show Dr. Rick Offerman who speaks to his experience as a process chemist, the drug development process and what goes into selecting a solvent
  • 15:41 – The importance of selecting the right CMO partner
  • 19:05 – Questions that must be asked in the beginning of the drug manufacturing process
  • 23:14 – Dr. Rick breaks down best practices in cost-control
  • 30:16 – The importance of the project timeline
  • 40:13 – Dr. Rick takes a moment to recognize those who greatly influenced his career
  • 46:23 – Ed, Brian and Meranda thank Dr. Rick for joining the show

Tweetable Quotes

“A lot of CMOs are now going to a ‘one-stop shop’ type model. So basically they’ll say, ‘Yeah we’ll take you all the way from gram quantities right through commercial. We can do your API and your drug substance.’ But there’s still a lot of smaller shops out there that can do small scale pre-clinical work.”

“Cost is always a factor [in selecting a solvent] but it’s not the major one.”

“You’re gotta have an integrated approach all the way through the system to understand the API that you’re producing, the impurity profile, the crystal morphology, the polymorphs, that sort of thing.”

“Realistically, when you look at the cost of an API as a percentage of a drug product, it’s usually fairly low.”

“If the analytical people aren’t up and ready to go, then when the chemists start running stuff in the hoods, how do they analyze it? We don’t have methods, so we’re kinda going on a wing and a prayer.”

Relevant Links

Design Space InPharmatics - LinkedIn

Design Space InPharmatics - Twitter

Edward Narke on LinkedIn

Rick Offerman on LinkedIn

  continue reading

27 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide